Mitochondrial-oriented micronutritional interventions show mechanistic plausibility but limited clinical efficacy in ME/CFS and fibromyalgia
This narrative review examines the evidence for micronutrient-based therapies targeting mitochondrial dysfunction in ME/CFS and fibromyalgia. It finds that while mechanistic plausibility is strong for several interventions (e.g., NAD+ precursors, CoQ10, magnesium), disease-specific randomized controlled evidence remains limited. The review calls for future RCTs, with one planned for 2027.
This article is automatically generated from the structured evidence profile behind the claim above. Scores reflect the quality and quantity of available research, not clinical advice.
Mitochondrial-oriented micronutritional interventions show mechanistic plausibility but limited clinical efficacy in ME/CFS and fibromyalgia The current body of evidence comprises 1 study. EvidenceHub rates the overall confidence at 32/100 (low).
The Claim
Mitochondrial-oriented micronutritional interventions show mechanistic plausibility but limited clinical efficacy in ME/CFS and fibromyalgia
This conclusion is most relevant to: Patients with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and fibromyalgia.
What the Research Shows
The conclusion draws on 1 linked study. Highlights from the cited literature:
- ▸Micronutrition as a Therapeutic Strategy for Mitochondrial Dysfunction in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome and Fibromyalgia: A Narrative Review. (Nutrients, 2026) —
How It Works
The proposed biological pathway:
- ▸Mitochondrial dysfunction and oxidative/nitrosative stress are implicated in ME/CFS and fibromyalgia
- ▸Micronutrients are essential for mitochondrial bioenergetics and antioxidant defense
- ▸Supplementation may restore mitochondrial function and reduce oxidative stress
- ▸Potential improvement in fatigue and related symptoms
Who Might Benefit
Evidence fit by population:
- ▸Patients with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and fibromyalgia
Recommended Dose
N/A
Limitations & Caveats
Important context when interpreting this evidence:
- ▸Narrative review, not systematic, may have selection bias
- ▸Limited disease-specific RCT evidence for most interventions
- ▸No quantitative meta-analysis or effect sizes provided
Frequently Asked Questions
What micronutrients are reviewed for mitochondrial support in ME/CFS and fibromyalgia?▼
The review covers NAD+ precursors, B-complex vitamins, magnesium, coenzyme Q10, alpha-lipoic acid, GlyNAC, L-carnitine, pyrroloquinoline quinone, taurine, and creatine.
Is there strong clinical evidence for these micronutrient interventions?▼
No, the review states that disease-specific randomized controlled evidence remains limited for several interventions, despite mechanistic plausibility.
What is the planned future research?▼
A randomized, double-blind, placebo-controlled trial in fibromyalgia patients with clinically significant fatigue is planned for 2027, subject to ethics approval and registration.
What are the key mechanisms targeted by these micronutrients?▼
They target mitochondrial bioenergetics, antioxidant defense, and immune-metabolic regulation, addressing mitochondrial dysfunction and oxidative stress.
References
- 1.Abanades S, Fernández I, Capdevila N, Cardona F. “Micronutrition as a Therapeutic Strategy for Mitochondrial Dysfunction in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome and Fibromyalgia: A Narrative Review..” Nutrients, 2026. PMID: 42654282 DOI: 10.3390/nu18162702